Key Takeaways Rigel's Tavalisse posted $68.5M in H1 2025 sales, which increased 44% year over year.Rezlidhia sales rose 31% to $13.1M, with Gavreto adding incremental revenues in 1H 2025.R289 phase Ib study in MDS moves to dose expansion, with dose escalation data expected later in 2025.Rigel Pharmaceuticals (RIGL) is making continued advancement related to the development of its hematology and oncology pipeline and products. The company’s first product, Tavalisse (fostamatinib disodium hexahydrate), has be ...

Key Takeaways RIGL's Tavalisse drove $68.5M sales in H1 2025, up 44% year over year, driving top-line growth.RIGL raised its 2025 revenue outlook to $270-$280M on strong performance across its marketed products.FOLD's Galafold posted $233.1M H1 2025 sales, up 11% year over year, with patent protection to 2038.Both Rigel Pharmaceuticals (RIGL) and Amicus Therapeutics (FOLD) are developing and commercializing treatments for rare medical conditions where existing therapies are limited, with the goal of establi ...

Key Takeaways Rigel stock has jumped 76.7% in three months, fueled by strong momentum for Tavalisse.Tavalisse made up over 65% of net product sales in Q2 2025, the firm's best quarter yet.Rigel raised 2025 revenue guidance to $270-$280M, led by Tavalisse, Rezlidhia and Gavreto.Shares of Rigel Pharmaceuticals (RIGL) have rallied 76.7% in the past three months. This stock price rally can be attributed to growing investor confidence regarding the strong growth of the company’s lead drug, Tavalisse (fostamatini ...

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is one of the best affordable biotech stocks to invest in now. Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) reported its fiscal Q2 2025 results on August 5, with total revenue for the quarter reaching approximately $101.7 million. This included net product sales of $58.9 million and contract revenues from collaborations of $42.7 million. The company also generated $59.6 million in net income. Following the results, Jefferies analyst Eun Yang maintained a Hold ratin ...

Key Takeaways Tavalisse recorded $68.5M in H1 sales, up 44% year over year on strong new patient demand.Rigel raised the 2025 revenue forecast to $270-$280M, up from the prior guidance of $200-$210M.Rigel's other marketed products, Rezlidhia and Gavreto, also saw sales increases in H1 2025.Rigel Pharmaceuticals’ (RIGL) first product, Tavalisse (fostamatinib disodium hexahydrate), has been driving the majority of the company’s revenues. The drug remains a key top-line driver for the company.Tavalisse, an ora ...

欧洲药品管理局孤儿药资格认定 - 欧洲药品管理局授予rilzabrutinib治疗IgG4相关疾病的孤儿药资格 该资格针对影响不超过欧盟万分之五患者的罕见病[1] - 孤儿药资格旨在支持罕见病药物开发[1] Rilzabrutinib临床进展 - rilzabrutinib正在开展治疗IgG4相关疾病的II期研究 52周治疗数据显示疾病发作减少、疾病标志物改善和糖皮质激素减量[2] - 美国食品药品监督管理局近期也授予该药物治疗IgG4相关疾病的孤儿药资格[2] - 除IgG4相关疾病外 该药物还在美国、欧盟和其他国家开发用于多种其他罕见病[2] 免疫性血小板减少症适应症进展 - rilzabrutinib治疗免疫性血小板减少症的监管申请正在美国审评中 预计2025年8月29日获得最终决定[4] - 该药物已在美国、欧盟和日本获得免疫性血小板减少症适应症的孤儿药资格认定[3] - 美国食品药品监督管理局此前已授予该药物治疗免疫性血小板减少症的快速通道资格[4] - 除美国外 该药物治疗免疫性血小板减少症的申请还在欧盟和中国接受审评[4] 其他适应症开发状况 - 美国食品药品监督管理局此前授予rilzabrutinib治疗温抗体型自身免疫性溶血性贫血和镰状细胞病的孤儿药资格[5] - 该药物正在开展治疗温抗体型自身免疫性溶血性贫血的中期研究 尚未进入镰状细胞病的临床开发[5] - 该药物通过收购Principia Biopharma获得 目前还在中期研究中开发用于哮喘和慢性自发性荨麻疹等免疫介导疾病[5] 市场竞争格局 - 潜在获批后 rilzabrutinib可能面临现有已批准疗法的竞争[6] - Rigel Pharmaceuticals的Tavalisse（fostamatinib）用于治疗对先前治疗反应不足的慢性免疫性血小板减少症成人患者 2025年上半年销售额达6850万美元 同比增长44%[6] - Amgen的Uplizna（inebilizumab）于2025年4月获得美国食品药品监督管理局批准治疗IgG4相关疾病成人患者 成为首个且唯一获该机构批准的治疗药物[8] - Uplizna通过2023年收购Horizon Therapeutics获得 在美国还获批治疗视神经脊髓炎谱系障碍[8]